Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
To determine the effects of 12 weeks administration of different dose levels of ALV003 on the mucosal lining of the small intestine and symptoms in celiac disease patients.
Epistemonikos ID: 5ed9468aef5652709b86d09d82a3682e2edad983
First added on: May 11, 2024